Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2012 1
2013 8
2014 9
2015 6
2016 7
2017 10
2018 9
2019 7
2020 8
2021 3
2022 4
2023 1
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group. Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing …
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticason …
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N, Kaneko T. Horita N, et al. Int J Chron Obstruct Pulmon Dis. 2015 Apr 21;10:813-22. doi: 10.2147/COPD.S56067. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 25960646 Free PMC article. Review.
Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. ...Now, the Breezhaler is the only device that can provide lo …
Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Bre …
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Kerstjens HAM, et al. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653074 Clinical Trial.
The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoate, indacaterol acetate, and glycopyrronium bromide (MF-IND-GLY) versus ICS-LABA in patients with inadequately controlled asthma. …
The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoate, ind …
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Chapman KR, et al. Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-339. doi: 10.1164/rccm.201803-0405OC. Am J Respir Crit Care Med. 2018. PMID: 29779416 Free article. Clinical Trial.
OBJECTIVES: To evaluate the efficacy and safety of direct de-escalation from long-term triple therapy to indacaterol/glycopyrronium in nonfrequently exacerbating patients with chronic obstructive pulmonary disease (COPD). ...CONCLUSIONS: In patients with COPD withou …
OBJECTIVES: To evaluate the efficacy and safety of direct de-escalation from long-term triple therapy to indacaterol/glycopyrroniu …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Papi A, et al. Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Lancet. 2018. PMID: 29429593 Clinical Trial.
We aimed to compare a single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) versus a single-inhaler dual bronchodilator combination of indacaterol plus glycopyrronium (IND/GLY) in terms of the rate …
We aimed to compare a single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/F …
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
Singh D, Wild JM, Saralaya D, Lawson R, Marshall H, Goldin J, Brown MS, Kostikas K, Belmore K, Fogel R, Patalano F, Drollmann A, Machineni S, Jones I, Yates D, Tillmann HC. Singh D, et al. Respir Res. 2022 Feb 10;23(1):26. doi: 10.1186/s12931-022-01949-3. Respir Res. 2022. PMID: 35144620 Free PMC article. Clinical Trial.
RATIONALE: The long-acting beta(2)-agonist/long-acting muscarinic antagonist combination indacaterol/glycopyrronium (IND/GLY) elicits bronchodilation, improves symptoms, and reduces exacerbations in COPD. ...
RATIONALE: The long-acting beta(2)-agonist/long-acting muscarinic antagonist combination indacaterol/glycopyrronium (IND/GLY) …
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.
Cazzola M, Rogliani P. Cazzola M, et al. J Comp Eff Res. 2017 Oct;6(7):627-636. doi: 10.2217/cer-2017-0037. Epub 2017 Aug 25. J Comp Eff Res. 2017. PMID: 28840753 Free article.
Indacaterol/glycopyrronium has been the first long-acting beta(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination to be approved as a maintenance treatment in chronic obstructive pulmonary disease patients. ...Therefore, in addition to …
Indacaterol/glycopyrronium has been the first long-acting beta(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixe …
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, Sigrist T, Fitting JW, Schmidt U, Geiser T, Wild C, Kostikas K, Clemens A, Brutsche M. Salomon J, et al. Respir Res. 2017 Jan 11;18(1):13. doi: 10.1186/s12931-016-0498-1. Respir Res. 2017. PMID: 28077140 Free PMC article. Clinical Trial.
METHODS: This multicentre, randomised, double-blind, single-dose, cross-over, placebo-controlled study evaluated efficacy and safety of the free combination of indacaterol maleate (IND) and glycopyrronium bromide (GLY) versus IND alone on spirometric and body …
METHODS: This multicentre, randomised, double-blind, single-dose, cross-over, placebo-controlled study evaluated efficacy and safety of the …
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D. Hashimoto S, et al. Int J Chron Obstruct Pulmon Dis. 2016 Oct 11;11:2543-2551. doi: 10.2147/COPD.S111408. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27785010 Free PMC article. Clinical Trial.
METHODS: The SHINE was a 26-week, multicenter, randomized, double-blind, parallel-group study that evaluated safety and efficacy of indacaterol (IND)/glycopyrronium (GLY) 110/50 mug once daily (od) compared with GLY 50 mug od, IND 150 mug od, open-label tiotropium ( …
METHODS: The SHINE was a 26-week, multicenter, randomized, double-blind, parallel-group study that evaluated safety and efficacy of indac …
Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG. Cazzola M, et al. COPD. 2015 Apr;12(2):175-81. doi: 10.3109/15412555.2014.922172. Epub 2014 Sep 15. COPD. 2015. PMID: 25222881 Free article. Clinical Trial.
We aimed to explore whether the acute bronchodilation induced by indacaterol 150 mug and glycopyrronium bromide 50 mug is additive or synergistic with respect to monocomponents by testing the type of effect ex vivo on isolated human bronchi and then in vivo i …
We aimed to explore whether the acute bronchodilation induced by indacaterol 150 mug and glycopyrronium bromide 50 mug …
75 results